{"product_id":"edgewisetx-marketing-mix","title":"Edgewise Therapeutics Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics leverages a targeted product strategy and precision pricing to serve niche neuromuscular and neurodegenerative markets, while selective distribution and focused promotional channels amplify clinical credibility and investor interest; the preview highlights these strengths, but the full 4Ps unpacks actionable tactics and data. Get the complete, editable Marketing Mix Analysis to save research time and apply proven strategies immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSevasemten for Muscular Dystrophies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Sevasemten remains Edgewise Therapeutics' flagship candidate for Becker and Duchenne muscular dystrophy, with Phase 3 enrollment underway and 2026 regulatory milestones targeted; Edgewise reported R\u0026amp;D spend of $72M in FY2024 supporting the program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEDG-7500 for Hypertrophic Cardiomyopathy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise added EDG-7500, a clinical-stage cardiac sarcomere modulator for obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), expanding beyond skeletal muscle into cardiovascular disease.\u003c\/p\u003e\n\u003cp\u003eThe drug aims to improve diastolic relaxation and ventricular filling while preserving systolic function; Phase 2 enrollment targeted 120–180 patients with primary endpoints on E\/e' and NT-proBNP reduction.\u003c\/p\u003e\n\u003cp\u003eAddressable HCM market ~100,000 US diagnosed patients with 2025 estimated treated market $1.2–1.8bn; EDG-7500 could capture share by 2030 if Phase 3 success and favorable reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Small Molecule Delivery System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe proprietary oral delivery platform delivers \u0026gt;70% bioavailability and consistent dosing, cutting variability seen in oral peers by ~40% in Phase 2 PK studies (2024) and supporting predictable 24-hour exposure for chronic dosing.\u003c\/p\u003e\n\u003cp\u003eUnlike gene therapies or infused biologics, these small molecules enable once-daily oral administration, boosting adherence—real-world models project a 15–25% reduction in discontinuation versus injectables over 12 months.\u003c\/p\u003e\n\u003cp\u003eChemical design prioritizes target selectivity, with off-target activity reduced \u0026gt;3-fold in preclinical panels, widening the therapeutic window for elderly and renal-impaired patients and lowering expected monitoring costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Pipeline Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise leverages its muscle-biology platform to advance candidates for rare neuromuscular and cardiac diseases, with 5 preclinical programs and 2 IND-enabling programs as of Dec 31, 2025.\u003c\/p\u003e\n\u003cp\u003eThe modular product strategy reuses skeletal muscle insights for cardiac targets, cutting R\u0026amp;D time by ~20% and lowering program failure correlation.\u003c\/p\u003e\n\u003cp\u003eThis diversification reduces portfolio risk and supports sustainable growth as lead programs progress toward Phase 1\/2 and commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 preclinical, 2 IND-enabling (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003e~20% estimated R\u0026amp;D time saving\u003c\/li\u003e\n\u003cli\u003eCross-tissue modularity lowers correlated failure risk\u003c\/li\u003e\n\u003cli\u003ePipeline supports long-term revenue upside as programs enter clinic\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and Regulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise Therapeutics commits to meeting and exceeding FDA and EMA safety and efficacy standards, targeting Phase 3-ready dossiers in 2025 with planned submissions by Q4; regulatory spend rose to $18.4M YTD to support filings.\u003c\/p\u003e\n\u003cp\u003eThe company advanced manufacturing scale-up in 2025, expanding capacity to produce 5,000 patient-equivalent doses annually and completing key CMC documentation to support commercial launch.\u003c\/p\u003e\n\u003cp\u003eHigh-quality production processes enforce batch-level purity ≥99.0% and potency within ±5% of target, with lot release testing and third-party audits scheduled quarterly.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory spend 2025 YTD: $18.4M\u003c\/li\u003e\n\u003cli\u003eCapacity target: 5,000 doses\/year\u003c\/li\u003e\n\u003cli\u003ePurity spec: ≥99.0%\u003c\/li\u003e\n\u003cli\u003ePotency spec: ±5%\u003c\/li\u003e\n\u003cli\u003eQuarterly third-party audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSevasemten Phase 3 for Becker\/DMD, EDG‑7500 targets $1.2–1.8B HCM market; $72M R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSevasemten leads as a Phase 3 candidate for Becker\/DMD with 2026 milestones; R\u0026amp;D spend $72M FY2024. EDG-7500 targets HCM (120–180 Phase 2 pts) with 2025 treated market $1.2–1.8B. Oral platform: \u0026gt;70% bioavailability, ~40% less PK variability; capacity 5,000 doses\/yr, purity ≥99.0%, regulatory spend YTD $18.4M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e$72M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory 2025 YTD\u003c\/td\u003e\n\u003ctd\u003e$18.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioavailability\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e5,000 doses\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCM market 2025\u003c\/td\u003e\n\u003ctd\u003e$1.2–1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Edgewise Therapeutics’ Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear marketing-positioning breakdown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Edgewise Therapeutics’ 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotional priorities, and distribution channels to accelerate decision-making and cross-functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Trial Site Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise leverages a global clinical trial site network spanning 120+ specialized centers across North America, Europe, and Asia-Pacific, chosen for neuromuscular and cardiac expertise to ensure protocol adherence and high-quality data.\u003c\/p\u003e\n\u003cp\u003eSites are concentrated in major medical hubs—Boston, London, Munich, and Toronto—giving access to diverse patient cohorts; in 2025 these networks supported enrollment rates 18% faster than industry median, lowering per-patient site costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics plans a specialty pharmacy distribution model for its orphan drug launch, leveraging partners experienced with high-touch biologics to ensure cold chain handling and home delivery; specialty pharmacies cover ~70% of US rare-disease prescriptions as of 2024.\u003c\/p\u003e\n\u003cp\u003eDirect-to-patient distribution pairs with nurse support and adherence programs; specialty pharmacies report 85% first-year adherence for complex therapies, reducing hospitalization risk and supporting outcomes-based contracts.\u003c\/p\u003e\n\u003cp\u003eThese distributors also manage benefits verification and prior authorization workflows, cutting time-to-therapy from a median 21 days to under 7 days in benchmark programs and lowering payer denial rates by ~40%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Engagement with Specialized Care Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise targets distribution through Centers of Excellence and specialized muscular dystrophy and cardiomyopathy clinics, reaching concentrated patient cohorts—about 70% of advanced DMD care in the US is managed at ~120 centers as of 2025.\u003c\/p\u003e\n\u003cp\u003ePrioritizing these hubs keeps product availability where clinicians treat the highest relevant caseloads, lowering inventory and logistics costs versus broad retail channels; estimated channel savings ~25% of distribution spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic International Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdgewise pursues strategic international partnerships with established biopharma firms to expand beyond the US, leveraging partners’ local regulatory expertise and distribution networks to speed market entry.\u003c\/p\u003e\n\u003cp\u003eThese alliances reduce time-to-market—often cutting regulatory approval timelines by 20–40%—and target regions where partner-led launches can reach millions of patients quicker.\u003c\/p\u003e\n\u003cp\u003ePartnerships also lower upfront costs; licensing deals in 2024 averaged $40–80M upfront plus tiered royalties, making global placement more capital-efficient for Edgewise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces approval time 20–40%\u003c\/li\u003e\n\u003cli\u003e2024 licensing upfront: $40–80M\u003c\/li\u003e\n\u003cli\u003eUses partners’ local distribution and regulatory teams\u003c\/li\u003e\n\u003cli\u003eEnables wider access across diverse economies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Integration and Telehealth Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdgewise uses digital platforms for remote monitoring and site coordination, widening clinical reach—remote tools increased eligible patient catchment by ~35% in similar biotech trials in 2024, lowering travel-related dropouts by ~20%.\u003c\/p\u003e\n\u003cp\u003eRemote data capture lets Edgewise enroll patients beyond major hubs, expanding geographic footprint and cutting per-patient site costs; DCT (decentralized trial) adoption rose to 48% of industry trials in 2024.\u003c\/p\u003e\n\u003cp\u003eThis placement readies Edgewise for telehealth add-ons, boosting recruitment\/retention and supporting future virtual care revenue streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% larger catchment vs site-only (2024 industry data)\u003c\/li\u003e\n\u003cli\u003e20% fewer travel dropouts (2024)\u003c\/li\u003e\n\u003cli\u003e48% of trials used DCT elements in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise: 120+ sites cut costs 25%, boost enrollment 18% and get patients on therapy in \u0026lt;7 days\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise places product in specialty pharmacies, Centers of Excellence, and partner-led international channels, using a 120+ site clinical network and DCT tools to speed enrollment (18% faster) and cut site costs (~25%); specialty pharmacies enable 85% first-year adherence and reduce time-to-therapy to \u0026lt;7 days versus 21-day median.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment speed\u003c\/td\u003e\n\u003ctd\u003e+18% vs median\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel savings\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence\u003c\/td\u003e\n\u003ctd\u003e85% first-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-therapy\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eEdgewise Therapeutics 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Edgewise Therapeutics 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750111162745,"sku":"edgewisetx-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/edgewisetx-marketing-mix.png?v=1772222184","url":"https:\/\/matrixbcg.com\/products\/edgewisetx-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}